Navigation Links
Cancer risk for kidney transplant
Date:4/30/2010

Kidney transplant recipients are known to have a higher risk of cancer, compared to the general population, due to the need to take immunosuppressive drugs to prevent organ rejection. Results published today from a significant, long-term study suggest that no single medication appears to increase this cancer risk.

Evaluating data from 1983 in a randomised trial, researchers were able review trends among 481 patients over 20 years - providing the strongest evidence to date on the issue. A total of 226 patients in the trial developed at least one cancer. By 20 years post transplant, 27% of patients developed non-skin cancer and 48% of patients developed skin cancer no one treatment had a greater effect on cancer risk.

"We found that no particular immunosuppressive drug regimen appears to increase the risk of cancer among kidney transplant patients," said lead author Dr Martin Gallagher, The George Institute.

"What we did find is that the cancer risk is driven by many factors that are known at the time of transplantation such as age and smoking history, so that patients at especially high risk can be targeted at this time", he added.

The results, which were published today in the Journal of the American Society of Nephrology, reported that non-skin cancer was associated with increasing age and smoking history; skin cancer was associated with increasing age, non-brown eye color, fairer skin, and a functioning transplant. Therefore, patients at especially high risk can be monitored more closely and use preventive measures to protect against cancer.

"Much debate has focused on the effects of various agents and dose regimens, but our analysis would suggest that cancer risk is driven by total immune suppression rather than specific medications."

More than 11,000 Australians have received a kidney transplant in the last forty years. Kidney transplant survival rates are about 90% in the first year and over
'/>"/>

Contact: Emma Orpilla
eorpilla@george.org.au
612-823-8242
Research Australia
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Targeted therapy prolongs life in patients with HER2-positive breast cancer
2. New Drugs, New Combinations Fight Breast Cancer
3. Study Finds Possible Explanation for the Link Between Infertility and Breast/Ovarian Cancer Risks
4. MDS Nordions TheraSphere(R) for Unresectable Liver Cancer (HCC) Now Covered by Two Large U.S. Insurers
5. National Oncologist Group Warns: Current Health Care Reform Legislation Woefully Short In Addressing Cancer Care Crisis
6. Panel calls for reducing colorectal cancer deaths by striking down barriers to screening
7. Lung Cancer: Large Impact, Little Funding
8. Inflammation marker related to obesity is elevated in patients with pancreatic cancer
9. Prolactin blocks oncogene associated with poor prognosis in breast cancer
10. Older female cancer survivors have added health issues compared to their counterparts
11. Definitive study confirms chemo benefit in postmenopausal breast cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/13/2014)... Recently, MillionaireCasket.com, a well-known casket manufacturer from China, has ... the company’s chief executive officer has announced a new promotion ... offered at discounted prices, from 15 to 26 percent off. ... in huge demand in the current market. We are excited ... a lot of high quality products for sale. Many of ...
(Date:7/13/2014)... 13, 2014 Micro irrigation systems are ... water dispersal as wells as to maintain soil quality. ... projected to become a dominant revenue generator for manufacturers ... to reduce resource costs has led to the adoption ... and has further caused massive demand for micro irrigation ...
(Date:7/13/2014)... Fuel additives are chemicals, which are added ... kerosene, and so on, in order to enhance their ... corrosion effects caused by fuels and improving the combustion ... provide economies of scale in the long run, but, ... of the fuel products. , The various fuel additive ...
(Date:7/13/2014)... 2014 A Massachusetts couple who have ... risks associated with power morcellators ( http://www.gynecaremorcellatorlawsuit.com/ ) ... federal regulators, as they presented poignant testimony on the ... Administration (FDA) advisory panel meeting convened to address the ... Rochester Democrat and Chronicle, Dr. Hooman Noorchashm and his ...
(Date:7/13/2014)... Athletes with a certain genetic make-up ... according to research presented today at the American Orthopaedic ... The research marks the first of its kind investigating ... physical events that occur after a head injury. ... in the (GT)n genotype were four times more likely ...
Breaking Medicine News(10 mins):Health News:Cheap Oak Caskets Recently Unveiled By China Casket Manufacturer MillionaireCasket.com 2Health News:Agricultural Micro Irrigation System Market is Expected to Grow at a CAGR of 18.1%, from 2013 to 2018 - New Report by MicroMarket Monitor 2Health News:Agricultural Micro Irrigation System Market is Expected to Grow at a CAGR of 18.1%, from 2013 to 2018 - New Report by MicroMarket Monitor 3Health News:North America Fuel Additives Market is Expected to Reach $8,100 Million by 2017 - New Report by MicroMarket Monitor 2Health News:North America Fuel Additives Market is Expected to Reach $8,100 Million by 2017 - New Report by MicroMarket Monitor 3Health News:North America Fuel Additives Market is Expected to Reach $8,100 Million by 2017 - New Report by MicroMarket Monitor 4Health News:Couple Who Brought Attention to Morcellator Cancer Risks Testify on Second Day of FDA Advisory Panel Meeting, Bernstein Liebhard LLP Reports 2Health News:Couple Who Brought Attention to Morcellator Cancer Risks Testify on Second Day of FDA Advisory Panel Meeting, Bernstein Liebhard LLP Reports 3Health News:Couple Who Brought Attention to Morcellator Cancer Risks Testify on Second Day of FDA Advisory Panel Meeting, Bernstein Liebhard LLP Reports 4Health News:Genetic Factors May Be Responsible for Slowing Concussion Recovery in Athletes 2
... Asia are born and die without leaving a trace ... information on which to base public health decisions, a ... colleagues say in a paper published today (Oct. 29, ... However, affordable solutions exist to collect these vital statistics ...
... Treatment Times, Optimize Planning, Objectives and Offer Increased ... Oct. 29 Accuray,Incorporated (Nasdaq: ARAY ), ... today four new products designed to improve treatment ... in radiation delivery. These products are being launched ...
... Ongoing Oncology Program for MDX-1106, PRINCETON, N.J., ... Inc. (Nasdaq: MEDX ) announced today the ... with the U.S. Food &,Drug Administration (FDA) for ... a fully human anti-PD-1 antibody being,investigated for the ...
... SAN DIEGO, Oct. 29 Arena Pharmaceuticals,Inc. (Nasdaq: ... to,present at the BIOCOM Investor Conference on November 2, ... at the Marriott Del Mar Hotel in San,Diego, California. ... to provide a corporate overview of the company and,its ...
... Office of Technology and Intellectual Property, has received a ... Society of U.S.A. and Canada. , The award stems ... University of Chicago and the Mayo Clinic. The deal ... risk of side effects from a standard first-line treatment ...
... S.C., Oct. 29 The federal government has,approved ... Medicare,Advantage and Medicare Part D product offerings. Enrollment ... BlueCross, products include two PPO plans, Medicare Blue(SM) ... Blue(SM),Private; and two prescription drug plans, MedBlue(SM) Rx ...
Cached Medicine News:Health News:Scandal of invisibility plagues countries with no civil registries 2Health News:Scandal of invisibility plagues countries with no civil registries 3Health News:Accuray Announces Four New Products at Nation's Leading Radiation Oncology Meeting 2Health News:Accuray Announces Four New Products at Nation's Leading Radiation Oncology Meeting 3Health News:Accuray Announces Four New Products at Nation's Leading Radiation Oncology Meeting 4Health News:Accuray Announces Four New Products at Nation's Leading Radiation Oncology Meeting 5Health News:Ono and Medarex Announce Allowance of Investigational New Drug Application for Fully Human Anti-PD1 Antibody 2Health News:Ono and Medarex Announce Allowance of Investigational New Drug Application for Fully Human Anti-PD1 Antibody 3Health News:Ono and Medarex Announce Allowance of Investigational New Drug Application for Fully Human Anti-PD1 Antibody 4Health News:Arena Pharmaceuticals to Present at the BIOCOM Investor Conference 2Health News:Arena Pharmaceuticals to Present at the BIOCOM Investor Conference 3Health News:Gene screen patent leads to 'Deal of Distinction' 2
(Date:7/10/2014)... 11, 2014  Major advances in radiation therapy ... being highlighted in a three-day Oncology Summit taking ... July, 2014.  Renowned national and international cancer experts from ... and exchange knowledge on modern technologies making treatment ... The Summit will address a ...
(Date:7/10/2014)... Calif. , July 10, 2014 Integrated ... leader in advanced memory and analog IC solutions, today ... on Thursday, July 24, 2014, at 7:00 a.m. Pacific ... financial results for the fiscal 2014 third quarter ended ... call via telephone, dial 1-888-556-4997 before 6:50 a.m. Pacific ...
(Date:7/10/2014)... Quebec , July 10, 2014  Valeant Pharmaceuticals ... VRX) today announced it has completed the sale to ... and Dysport owned or held by Valeant for $1.4 ... with Nestle S.A, which recently completed its acquisition of ... the divestiture of our products to a company that ...
Breaking Medicine Technology:Improving quality and access to advanced cancer care in India and South Asia 2Improving quality and access to advanced cancer care in India and South Asia 3Improving quality and access to advanced cancer care in India and South Asia 4Improving quality and access to advanced cancer care in India and South Asia 5
... ActivBiotics, Inc. today,announced the results of its ... rifalazil in the treatment of intermittent claudication,associated ... demonstrated,that treatment for two months with the ... significant improvement in walking distance,claudication onset times, ...
... Scientific Sessions ... 2007 in Orlando, Florida, ... ) today announced the successful completion,of its Phase 2b trial ... vaccine being,developed to treat nicotine addiction and prevent smoking relapse. ...
Cached Medicine Technology:Rifalazil Trial (PROVIDENCE-1) Fails to Provide Significant Clinical Benefit in Patients With Peripheral Arterial Disease 2Rifalazil Trial (PROVIDENCE-1) Fails to Provide Significant Clinical Benefit in Patients With Peripheral Arterial Disease 3Nabi Biopharmaceuticals Announces Successful Completion of NicVAX(R) Phase 2b Trial; Drug Shows Statistically Significant Rates of Smoking Cessation and Continuous Long-Term Smoking Abstinence at 12 Months 2Nabi Biopharmaceuticals Announces Successful Completion of NicVAX(R) Phase 2b Trial; Drug Shows Statistically Significant Rates of Smoking Cessation and Continuous Long-Term Smoking Abstinence at 12 Months 3Nabi Biopharmaceuticals Announces Successful Completion of NicVAX(R) Phase 2b Trial; Drug Shows Statistically Significant Rates of Smoking Cessation and Continuous Long-Term Smoking Abstinence at 12 Months 4Nabi Biopharmaceuticals Announces Successful Completion of NicVAX(R) Phase 2b Trial; Drug Shows Statistically Significant Rates of Smoking Cessation and Continuous Long-Term Smoking Abstinence at 12 Months 5Nabi Biopharmaceuticals Announces Successful Completion of NicVAX(R) Phase 2b Trial; Drug Shows Statistically Significant Rates of Smoking Cessation and Continuous Long-Term Smoking Abstinence at 12 Months 6Nabi Biopharmaceuticals Announces Successful Completion of NicVAX(R) Phase 2b Trial; Drug Shows Statistically Significant Rates of Smoking Cessation and Continuous Long-Term Smoking Abstinence at 12 Months 7
Calcitonin EIA Bone and Mineral Metabolism 021-SDX017...
... an enzyme immunoassay (EIA) kit for the ... the subclass of Anti-Neutrophil Cytoplasmic Antibodies (ANCA) ... an aid in the diagnosis of crescentic ... with vasculitic disorders and glomerulonephritis (GN). They ...
Anti-PR3 EIA Auto-Immune Markers 013-PR3-96 Proteinase...
Anti-PR3 EIA Auto-Immune Markers 013-PR3-48 Proteinase...
Medicine Products: